Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jean-Yves Douillard MD, PhD
Jean-Yves Douillard MD, PhD Advisory Board
Lee Schwartzberg MD, FACP
Lee S. Schwartzberg MD, FACP Advisory Board
David Henry MD
David Henry MD Advisory Board
See All Experts
story of the week
Published in Oncology

Journal Scan / Research · March 21, 2019

Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study

Journal of Clinical Oncology

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Axel Grothey MD

Journal of Clinical Oncology
Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study
J. Clin. Oncol 2019 Mar 20;[EPub Ahead of Print], E Van Cutsem, S Huijberts, A Grothey, R Yaeger, PJ Cuyle, E Elez, M Fakih, C Montagut, M Peeters, T Yoshino, H Wasan, J Desai, F Ciardiello, A Gollerkeri, J Christy-Bittel, K Maharry, V Sandor, JHM Schellens, S Kopetz, J Tabernero

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated